# US 2026/0061010 A1 · Use of bacterial strain for enhancing 5-hydroxytryptophan secretion by enterochromaffin cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061010 A1
- Document ID: US20260061010A1
- Status: Published application
- Kind: A1
- Application number: 18/818,794
- Filed: 2024-08-29
- Published: 2026-03-05
- Earliest claimed: 2023-11-28
- Assignees: Glac Biotech Co., Ltd.
- Applicants: Glac Biotech Co, Ltd.
- Inventors: HSIEH-HSUN HO; YI-WEI KUO; JIA-HUNG LIN; SHIN-YU TSAI; CHING-MIN LI; YU-CHIEH HSU; KO-CHIANG HSIA; JUI-FEN CHEN; YEN-YU HUANG
- Web page: https://patentgrep.com/patent/US20260061010A1

## CPC

- A61K 35/745: Bifidobacteria
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

A method for enhancing 5-hydroxytryptophan secretion by enterochromaffin cells is disclosed, and the method comprises: administering a composition to a subject in need thereof, the composition comprising: a Bifidobacterium animalis subsp. lactis BB-115 strain. Herein, another method for enhancing 5-hydroxytryptophan secretion by enterochromaffin cells through administering a composition to a subject in need thereof, the composition comprising: a Bifidobacterium animalis subsp. lactis BB-115 strain, a Lactobacillus rhamnosus MP108 strain, and a Bifidobacterium longum subsp. infantis BLI-02 strain.

## Claims

### Claim 1

A method for enhancing 5-hydroxytryptophan secretion by enterochromaffin cells, comprising:
administering a composition to a subject in need thereof;
wherein the composition comprises: a Bifidobacterium animalis subsp. lactis BB-115 strain deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 21840.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the Bifidobacterium animalis subsp. lactis BB-115 strain is an active strain or an inactivated strain.

### Claim 3 (depends on 1)

The method as claimed in claim 1, being further for enhancing immunity, treating insomnia, treating depression, treating hypertension, improving somnipathy, improving anxiety, improving inattention, treating menopausal syndrome, or treating gastrointestinal disease.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the composition is a medicine, a food, or a health supplement.

### Claim 5

A method for enhancing 5-hydroxytryptophan secretion by enterochromaffin cells, comprising:
administering a composition to a subject in need thereof;
wherein the composition comprises: a Bifidobacterium animalis subsp. lactis BB-115 strain deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 21840, a Lactobacillus rhamnosus MP108 strain deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 21225, and a Bifidobacterium longum subsp. infantis BLI-02 strain deposited at the China General Microbiological Culture Collection Center with a deposition number of CGMCC 15212.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the Bifidobacterium animalis subsp. lactis BB-115 strain is an active strain or an inactivated strain.

### Claim 7 (depends on 5)

The method as claimed in claim 5, wherein the Lactobacillus rhamnosus MP108 strain is an active strain or an inactivated strain.

### Claim 8 (depends on 5)

The method as claimed in claim 5, wherein the Bifidobacterium longum subsp. infantis BLI-02 strain is an active strain or an inactivated strain.

### Claim 9 (depends on 5)

The method as claimed in claim 5, wherein a CFU (colony forming unit) ratio of the Bifidobacterium animalis subsp. lactis BB-115 strain to the Lactobacillus rhamnosus MP108 strain to the Bifidobacterium longum subsp. infantis BLI-02 strain is (1 to 2): 1:1.

### Claim 10 (depends on 5)

The method as claimed in claim 5, wherein a CFU (colony forming unit) ratio of the Bifidobacterium animalis subsp. lactis BB-115 strain to the Lactobacillus rhamnosus MP108 strain to the Bifidobacterium longum subsp. infantis BLI-02 strain is 2:1:1.

### Claim 11 (depends on 5)

The method as claimed in claim 5, being further for enhancing immunity, treating insomnia, treating depression, treating hypertension, improving somnipathy, improving anxiety, improving inattention, treating menopausal syndrome, or treating gastrointestinal disease.

### Claim 12 (depends on 5)

The method as claimed in claim 5, wherein the composition is a medicine, a food, or a health supplement.
